“HYTN”, a pharmaceutical company specializing in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its approval for trading on the OTC PINK Market ("OTC PINK") effective July 29th, 2024, under the trading symbol “HYTNF”.

"HYTN", a leader in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce, further to its news release dated June 13, 2024, the completion of its acquisition (“Acquisition”) of all of the issued and outstanding share capital of Prism Scientific Labs Inc. (Prism), a company focussed on the research and development of psychedelic and psychoactive compounds, with a particular emphasis on enhancing tryptamine yields in psychedelic mushrooms.

“HYTN”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has been granted a Drug Establishment License (DEL) by Health Canada.

HYTN is pleased to announce that that it has entered into an agreement (the “Purchase Agreement”) to acquire (the “Transaction”) 100% of the issued and outstanding share capital of Prism Scientific Labs Inc.

HYTN is pleased to announce that it has engaged the services of Independent Trading Group (”ITG”) as a market maker for its shares traded on the Canadian Securities Exchange (“CSE”).

HYTN is pleased to announce the results of its annual general and special meeting of shareholders held on May 23, 2024 (the “AGSM”).

is pleased to announce that it has closed its previously announced nonbrokered private placement of units of the Company (“Units”) by issuing a total of 9,980,670 Units at a price of $0.075 per Unit (the “Offering”) for aggregate gross proceeds of $748,550.25.

HYTN Press Release